SDF2L1 Antibody

What is SDF2L1 and why is it important in research?

SDF2L1 is an endoplasmic reticulum (ER)-resident protein expressed in a wide variety of tissues. It functions as a component of the ER chaperone complex and interacts with other chaperone proteins including BiP and co-chaperone Erj3 . SDF2L1 plays crucial roles in:

• Protein quality control in the ER

• Regulation of ER-associated degradation (ERAD)

• ER stress response

• Interaction with various defensin propeptides

• Potential tumor suppression

Research methodologies leveraging SDF2L1 antibodies have revealed that this protein increases in response to ER stress-inducing compounds and may act as a buffer for substrate availability for ERAD, particularly in pancreatic β-cells .

What applications are supported by current SDF2L1 antibodies?

Current commercially available SDF2L1 antibodies support multiple research applications with varying recommended dilutions:

Researchers should note that optimal working dilutions must be determined empirically as they may be sample-dependent .

What tissue/sample types are most suitable for SDF2L1 antibody research?

Based on validated antibody testing, researchers can reliably detect SDF2L1 in:

• Human: testis, pancreas, and small intestine tissues

• Mouse: pancreas and testis tissues

• Rat: pancreas and testis tissues

When designing experiments, consider that SDF2L1 is ubiquitously expressed but may show tissue-specific regulation patterns, particularly under ER stress conditions .

How should researchers optimize SDF2L1 detection in western blot experiments?

For optimal western blot detection of SDF2L1:

• Sample preparation: Use RIPA buffer with protease inhibitors for efficient extraction

• Protein loading: Load 20-50 μg of total protein per lane

• Membrane selection: PVDF membranes show superior retention of SDF2L1

• Blocking: 5% non-fat milk in TBST for 1 hour at room temperature

• Primary antibody incubation: Follow recommended dilutions (1:1000-1:4000) in blocking buffer overnight at 4°C

• Detection: The predicted molecular weight of SDF2L1 is 24 kDa, though some tissues may show additional bands at 37 kDa

To validate specificity, include positive control tissues (pancreas or testis) and consider using recombinant SDF2L1 protein as an additional control .

What are the best methods for immunohistochemical detection of SDF2L1?

For optimal immunohistochemical detection:

• Fixation: Use formalin-fixed, paraffin-embedded (FFPE) tissues

• Antigen retrieval: Test both TE buffer pH 9.0 and citrate buffer pH 6.0 for optimal results

• Antibody concentration: Start with 5-20 μg/mL for IHC applications

• Visualization method: DAB staining provides good contrast

• Counterstaining: Hematoxylin for nuclear visualization

For negative controls, use non-immune IgG at the same concentration as the primary antibody .

How can researchers minimize background and maximize specificity in SDF2L1 immunostaining?

To enhance specificity while reducing background:

• Optimize blocking: Extended blocking (2 hours) with 3% BSA in PBS can reduce non-specific binding

• Titrate antibody: Test a range of concentrations to identify optimal signal-to-noise ratio

• Include absorption controls: Pre-incubate antibody with recombinant SDF2L1 protein

• Optimize wash steps: Increase wash duration and number of washes in 0.1% Tween-20 in PBS

• Use fluorescent secondary antibodies: These can provide better signal-to-noise ratios than enzymatic detection methods for challenging samples

Researchers should validate staining patterns by comparing with published expression data from resources like the Human Protein Atlas .

How can SDF2L1 antibodies be used to investigate protein-protein interactions in the ER chaperone complex?

For studying SDF2L1's interactions with other ER components:

• Co-immunoprecipitation (Co-IP):

  • Use SDF2L1 antibody conjugated to protein A/G beads

  • Lyse cells in non-denaturing buffers (e.g., NP-40 buffer)

  • Precipitate SDF2L1 and probe for interacting partners (BiP, Erj3)

  • Include appropriate controls (IgG, input)

• Proximity ligation assay (PLA):

  • Use SDF2L1 antibody with antibodies against putative interacting partners

  • Visualize interactions directly in fixed cells

  • Quantify interaction signals using image analysis software

Research has demonstrated that SDF2L1 interacts with the ER chaperone GRP78/BiP, the ERAD machinery, and with misfolded proteins like proinsulin . When designing interaction studies, consider that SDF2L1 has three distinct MIR domains that may mediate different protein-protein interactions .

What are the experimental considerations when using SDF2L1 antibodies to study ER stress and the unfolded protein response?

When investigating ER stress:

• Induction methods:

  • Pharmacological (tunicamycin, thapsigargin)

  • Expression of misfolded proteins

  • Physiological stress (glucose deprivation, hypoxia)

• Time course analysis:

  • SDF2L1 protein levels increase in response to ER stress

  • Monitor expression at multiple timepoints (4, 8, 12, 24 hours)

  • Compare with established ER stress markers (BiP, CHOP)

• Subcellular fractionation:

  • Isolate ER fractions to enrich for SDF2L1

  • Compare expression in different cellular compartments

• Functional analysis:

  • Knockdown/overexpression of SDF2L1 affects substrate degradation kinetics

  • Consider pulse-chase experiments to track protein degradation rates

Research has shown that SDF2L1 protein levels are specifically induced by ER stress-inducing compounds and by expression of misfolded proteins, suggesting a role in regulating protein quality control pathways .

How can researchers utilize SDF2L1 antibodies to investigate its role in disease pathogenesis?

For disease-focused research:

• Cancer studies:

  • SDF2L1 acts as a potential tumor suppressor in nasopharyngeal carcinoma

  • Compare expression in tumor vs. normal tissues using IHC

  • Correlate expression with clinical parameters

  • Tissue microarray analysis for high-throughput screening

• Diabetes/β-cell dysfunction research:

  • SDF2L1 is induced in islets from diabetic mice

  • Study interaction with misfolded proinsulin

  • Analyze role in ER stress-induced β-cell apoptosis

• Genetic manipulation approaches:

  • Knockdown/overexpression affects cell migration, invasion, and proliferation

  • Consider stable cell lines with modulated SDF2L1 expression

  • Rescue experiments to confirm specificity

Studies have shown that SDF2L1 inhibits nasopharyngeal carcinoma cell proliferation, migration, and invasion, suggesting therapeutic potential . Additionally, SDF2L1 interacts with the ERAD machinery and retards the degradation of mutant proinsulin, indicating a role in diabetes pathogenesis .

What are common challenges when working with SDF2L1 antibodies and how can they be addressed?

When troubleshooting, always include positive control tissues (pancreas, testis) where SDF2L1 is known to be expressed .

How can researchers validate the specificity of their SDF2L1 antibody results?

For comprehensive validation:

• Genetic controls:

  • siRNA/shRNA knockdown of SDF2L1

  • CRISPR-Cas9 knockout cell lines

  • Overexpression systems (compare with empty vector)

• Peptide competition:

  • Pre-incubate antibody with immunizing peptide

  • Signal should be reduced/abolished

• Multiple antibody validation:

  • Test multiple antibodies targeting different epitopes

  • Compare staining patterns and localization

• Cross-species analysis:

  • SDF2L1 is conserved across species; similar pattern should be observed

• Correlation with mRNA expression:

  • Compare protein detection with qRT-PCR data

  • Tissues with high mRNA should show corresponding protein levels

Research has demonstrated that SDF2L1 mRNA levels in NPC tissues (0.549 ± 0.568) were significantly lower than in chronic nasopharyngitis tissues (1.254 ± 0.729) , providing a baseline for expected expression patterns.

What considerations should be made when designing experiments to study SDF2L1 MIR domain functions using domain-specific antibodies?

When investigating SDF2L1 domain functions:

• Domain structure considerations:

  • SDF2L1 has three MIR domains (MIR1: residues 35-87, MIR2: 95-150, MIR3: 151-205)

  • MIR3 is sufficient for interaction with α- and β-defensins but not θ-defensins

  • Consider epitope location relative to functional domains

• Domain-specific interactions:

  • MIR domain deletion mutants show differential binding to defensin subtypes

  • Immunoprecipitation with domain-specific antibodies may pull down different interaction partners

• Structural considerations:

  • 3D model of SDF2L1 shows compact structure of three MIR domains

  • Antibody accessibility to specific domains may vary

Research has shown that SDF2L1 interacts differently with θ-defensin precursors compared to α- and β-prodefensins, with the MIR3 domain being sufficient for interaction with proHNP3, proHD5, and proHBD1, but not with proRTD1a .

How can researchers utilize SDF2L1 antibodies to investigate its role in the integrated stress response?

For integrated stress response studies:

• Analytical approaches:

  • Compare SDF2L1 induction across different stress types (ER stress, oxidative stress, nutrient deprivation)

  • Monitor kinetics of induction relative to canonical stress markers

  • Analyze transcription factor binding to SDF2L1 promoter

• Experimental design:

  • Establish stress-specific time courses

  • Compare pharmacological vs. physiological stress inducers

  • Consider cell type-specific responses

• Functional assessment:

  • Determine if SDF2L1 knockdown affects cell viability under different stress conditions

  • Analyze activation of downstream stress pathways (PERK, IRE1, ATF6)

Data shows that SDF2L1 protein levels are specifically increased in response to ER stress-inducing compounds, but not other cell stressors tested in insulinoma cell lines , suggesting a selective role in ER stress pathways rather than general cellular stress.

What methodologies are optimal for studying SDF2L1's role in protein quality control and ERAD systems?

For protein quality control and ERAD research:

• Kinetic analysis:

  • Pulse-chase experiments to track degradation rates of ERAD substrates

  • Compare degradation kinetics with and without SDF2L1

  • Use proteasome inhibitors to confirm ERAD involvement

• Interaction mapping:

  • Identify binding regions between SDF2L1 and ERAD components

  • Use deletion mutants to map minimal interaction domains

  • In vitro binding assays with purified components

• Live cell imaging:

  • Fluorescent ERAD substrates to track degradation in real-time

  • FRAP (Fluorescence Recovery After Photobleaching) to assess mobility of SDF2L1

  • Split fluorescent protein assays for direct visualization of interactions

Research has shown that knockdown of SDF2L1 in INS-1 (insulin 2 C96Y-GFP) cells unexpectedly increased the degradation kinetics of mutant proinsulin, suggesting that SDF2L1 regulates substrate availability for the ERAD system and increases the time misfolded proteins have to achieve correct folding .

How can researchers investigate the potential tumor suppressor role of SDF2L1 in different cancer types?

For cancer-related SDF2L1 research:

• Expression analysis across cancer types:

  • Tissue microarrays with multiple cancer types

  • Compare expression in paired tumor/normal tissues

  • Correlate with clinical parameters (stage, grade, survival)

• Functional validation:

  • Stable overexpression/knockdown in cancer cell lines

  • Analyze effects on:

    • Cell proliferation (CCK-8 assay, cell clone formation)

    • Migration (scratch migration assay, Transwell migration)

    • Invasion (Transwell invasion assay)

    • Cell cycle progression (flow cytometry)

• Molecular mechanism investigation:

  • Identify downstream targets using RNA-seq

  • ChIP-seq to identify transcription factors regulating SDF2L1

  • Pathway analysis of affected genes

Research in nasopharyngeal carcinoma has shown that SDF2L1 is downregulated in cancer tissues (positive rate of 20.6% in NPC vs. 91.4% in chronic nasopharyngitis), and overexpression of SDF2L1 inhibited cell proliferation, migration, and invasion, while knockdown had opposite effects .